Huntsman Corporation announced a cash dividend of $0.0875 per share on its common stock, payable on December 11, 2026, to shareholders recorded by November 27, 2026. This dividend reflects the company's ongoing commitment to returning value to its investors. Huntsman operates globally in the chemical manufacturing sector, with revenues around $6 billion in 2025 and a broad product range serving diverse markets. Investors should note the company also highlighted potential risks affecting future operations and financial results.
Huntsman Corporation's dividend announcement is presented here with Pluang's Basic Materials sector data as of Nov 12, 2026 04:11 WIB. For readers following this sector, 36 of 83 priced US stocks rose while 47 fell. Notable movers include Standard Lithium Ltd at USD 1.46 with a 1-day change of -5.81% and a Pluang order activity of 72% Sell / 28% Buy, Kinross Gold Corporation at USD 21.65 down 5.25% with 18% Sell / 82% Buy, and USA Rare Earth Inc. Class A Common Stock at USD 8.28 up 4.55% with 57% Sell / 43% Buy. The most notable figure is Standard Lithium Ltd's 72% sell order activity.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
